drugset
drugset / Trial / NCT07189871

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871 ↗

Phase 1/2 Recruiting 61 enrolled Radiopharm Theranostics, Ltd Medpace, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Timeline

Start
2026-02-23
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-BetaBart Monoclonal antibody — Intravenous

Indications

castration-resistant prostate carcinoma cervical cancer colorectal cancer endometrial cancer esophageal squamous cell carcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian carcinoma small cell lung carcinoma triple-negative breast carcinoma